Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 7/20 | 0.37 |
| ▸ | RAF1 | P04049 | 3/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 3/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6480073 | 1.00 | P2RX3 (0.37) | P2RX3RAF1RIPK1BRAFBTK | |
| SCHEMBL6478848 | 0.86 | P2RX3 (0.38) | P2RX3SPHK1OPRK1KCNH2 | |
| SCHEMBL6478853 | 0.86 | P2RX3 (0.38) | P2RX3SPHK1OPRK1KCNH2 | |
| SCHEMBL6479847 | 0.84 | OPRM1 (0.42) | P2RX3 | |
| SCHEMBL6479854 | 0.84 | OPRM1 (0.42) | P2RX3 | |
| SCHEMBL2288435 | 0.83 | SPHK1 (0.39) | BTKSPHK1 | |
| SCHEMBL6487557 | 0.83 | SPHK1 (0.39) | BTKSPHK1 | |
| SCHEMBL2291830 | 0.83 | SMN1; SMN2 (0.40) | SPHK1 | |
| SCHEMBL6487562 | 0.83 | SPHK1 (0.39) | BTKSPHK1 | |
| SCHEMBL6486940 | 0.82 | BRD4 (0.46) | SPHK1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-10-03 | — | — | US | disclosed |
| EP-1140849-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040560-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB2, ADRB3 | P2RX3 1025/4885RAF1 1201/4885RIPK1 4731/4885 |
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB2, ADRB1, ADRB3 | P2RX3 363/4885RAF1 2033/4885RIPK1 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.